EFFICACY AND SAFETY OF VOCLOSPORIN IN PATIENTS WITH PROTEINURIA ≥2 MG/MG: AN INTEGRATED ANALYSIS OF THE AURA-LV AND AURORA 1 STUDIES (ERA-EDTA 2023) - Apr 15, 2023 - Abstract ##3032; Pres time: Jun 18, 2023; 09:17 AM - 09:30 AM; Location: Brown 3; "Consistent with results from the overall pooled study population, patients with UPCR ≥2 mg/mg at baseline treated with voclosporin achieved significantly higher renal response rates and significantly earlier reductions in UPCR than patients treated with MMF and low-dose steroids alone. These findings are clinically important given the lack of effective therapies available for patients with high baseline proteinuria."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Salem Almaani1; Emily Littlejohn2; Lucy Hodge3; Christopher Mela3; Christopher Collins3
|